688177 Bio-Thera Solutions,
- 21.65
- +0.28+1.31%
Bio-Thera Solutions, News
Biotech Investor Relations Activity Record Form (2024 Third Quarter Results Briefing)
Biotech voluntarily disclosed information about its relationship with Gedeon Richter Plc. (Jiri Pharmaceuticals) Progress Notice on Signing a License and Receiving Down Payments and Milestone Payments for BAT2206 (usinumab) injections and production, supply and commercialization agreements
Biotech\'s announcement on holding a results briefing for the third quarter of 2024
Biotech 2024 Third Quarter Report
Baiaotai\'s announcement on plans for shareholders holding 5% or more of the shares to reduce their shareholding
Biotech: Biotech on Gedeon Richter Plc. (Jiri Pharmaceuticals) Announcement on the signing of licensing and production, supply and commercialization agreements for BAT2206 (usinumab) injections
Biotech About Gedeon Richter Plc (Jiri Pharmaceuticals) Announcement on the signing of licensing and production, supply and commercialization agreements for BAT2206 (usinumab) injection
Announcement that shareholders holding 5% or more of Baiaotai\'s shares have not reduced their holdings at the end of the planned period
Biotech Investor Relations Activity Record Form (2024 Semi-Annual Science and Technology Innovation Board Pharmaceutical and Biological Products Group Performance Briefing)
Biotech Investor Activity Record Form (2024 Investor Online Group Reception Day Event in Guangdong Province)
Baiaotai\'s announcement on participating in the 2024 Semi-Annual Science and Technology Innovation Board Special Group Performance Briefing on Pharmaceuticals and Biological Products
Baiaotai\'s announcement on participating in the 2024 Investor Online Group Reception Day in Guangdong
Biotech voluntarily disclosed the notice of approval for dupriumab injection (BAT2406) for drug clinical trials
Biotech voluntarily disclosed the notice of approval for clinical trials of BAT8006 combined with bevacizumab
China International Finance Co., Ltd.'s verification opinion on Bio-Thera Solutions Co., Ltd.'s use of part of the idle funds raised to temporarily supplement working capital.
Bio-Thera Solutions' Announcement Regarding the Temporary Supplement of Working Capital Using Some Idle Raised Funds
Bio-Thera Solutions' semi-annual evaluation report on the special action plan for improving quality and efficiency and returning to profitability in the company for the year 2024.
Bio-Thera Solutions 2024 Semi-Annual Report
Announcement of the resolution of the 15th meeting of the second board of supervisors of Bio-Thera Solutions.
Bio-Thera Solutions Special Report on the Deposit and Actual Use of Funds Raised in the First Half of 2024
Analysis
Price Target
No Data
No Data